Inventor · disambiguated record
Anilkumar G. Nair
Also filed as: NAIR ANILKUMAR · NAIR ANILKUMAR G · NAIR ANILKUMAR GOPINADHAN
13 granted patents·13 pending applications·81 citations·filing 2009–2024
89Inventor score
Files withMERCK SHARP & DOHME8MERCK SHARP & DOHME LLC8NAIR ANILKUMAR G3DWYER MICHAEL P2CHEN KEVIN X1
Top patents by PatentIndex Score
26 records- 0194US9227973B2Pyridine CGRP receptor antagonistsMERCK SHARP & DOHME·Filed 2013·Granted Jan 5, 2016·16 cites·4 claims
- 0290US9296750B2Spirolactam CGRP receptor antagonistsMERCK SHARP & DOHME·Filed 2013·Granted Mar 29, 2016·16 cites·3 claims
- 0390US9227972B2Aliphatic spirolactam CGRP receptor antagonistsMERCK SHARP & DOHME·Filed 2013·Granted Jan 5, 2016·17 cites·4 claims
- 0485US9932311B2Antidiabetic tricyclic compoundsMERCK SHARP & DOHME·Filed 2014·Granted Apr 3, 2018·4 cites·24 claims
- 0583US11427616B2PCSK9 antagonist compoundsMERCK SHARP & DOHME LLC·Filed 2019·Granted Aug 30, 2022·3 cites·48 claims
- 0682US8772505B2Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis CCHEN KEVIN X·Filed 2010·Granted Jul 8, 2014·8 cites·14 claims
- 0780US8980920B2Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis CZENG QINGBEI·Filed 2010·Granted Mar 17, 2015·8 cites·8 claims
- 0879US2025206781A1Pcsk9 antagonist compoundsMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 0978US8609635B2Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseasesNAIR ANILKUMAR GOPINADHAN·Filed 2011·Granted Dec 17, 2013·8 cites·39 claims
- 1073US12209145B2PCSK9 antagonist compoundsMERCK SHARP & DOHME LLC·Filed 2022·Granted Jan 28, 2025·0 cites·29 claims
- 1167US10968193B2Antidiabetic bicyclic compoundsMERCK SHARP & DOHME·Filed 2015·Granted Apr 6, 2021·1 cites·11 claims
- 1258US2025223290A1Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3MERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 1358US2025195511A1Indazole derivatives useful as inhibitors of nod-like receptor protein 3MERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 1457US2024124451A1Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3MERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 1552US2023399341A17-phenyl substituted 2-aminoquinazoline inhibitors of hpk1MERCK SHARP & DOHME LLC·Filed 2021·Application pending·0 cites
- 1652US2023416225A1Diaminopyrimidine carboxamide inhibitors of hpk1MERCK SHARP & DOHME LLC·Filed 2021·Application pending·0 cites
- 1748US2023066268A1Indazole derivatives and methods of use thereof for the treatment of herpes virusesCOOKE ANDREW JOHN·Filed 2020·Application pending·0 cites
- 1846US10519115B2Antidiabetic tricyclic compoundsMERCK SHARP & DOHME·Filed 2014·Granted Dec 31, 2019·0 cites·21 claims
- 1945US8901139B2Tricyclic indole derivatives and methods of use thereofVENKATRAMAN SRIKANTH·Filed 2009·Granted Dec 2, 2014·0 cites·19 claims
- 2045US2015087641A1Heterocyclic cgrp receptor antagonistsMERCK SHARP & DOHME·Filed 2013·Application pending·0 cites
- 2141US2013345254A1Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonistsNAIR ANILKUMAR G·Filed 2012·Application pending·0 cites
- 2241US2014005165A1Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonistsNAIR ANILKUMAR G·Filed 2012·Application pending·0 cites
- 2341US2014378416A1Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseasesDWYER MICHAEL P·Filed 2012·Application pending·0 cites
- 2441US2015057246A1Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseasesDWYER MICHAEL P·Filed 2012·Application pending·0 cites
- 2540US2014005174A1Indole derivatives useful as ccr2 antagonistsNAIR ANILKUMAR G·Filed 2012·Application pending·0 cites
- 2634US10000454B2Antidiabetic tricyclic compoundsMERCK SHARP & DOHME·Filed 2015·Granted Jun 19, 2018·0 cites·22 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →